title: Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage.
abstract: BACKGROUND
  Accumulating evidence established a positive association of anti-heat shock protein 60 (HSP60) autoantibodies and the presence of atherosclerosis in humans. However, whether these autoantibodies play a causal role in the development of atherosclerosis is unknown.
  
  
  RESULTS
  In the present study, anti-HSP60 autoantibodies from blood of patients with coronary heart disease were isolated by affinity chromatography and injected into the tail vein of apolipoprotein E-deficient mice. Atherosclerotic lesions in aortas were significantly increased 8 weeks after injection. Furthermore, administration of a specific mouse monoclonal antibody (II-13) recognizing amino acid residues 288 to 366 of HSP60 effectively induced atherosclerotic lesions in apolipoprotein E-deficient mice. II-13 injection resulted in endothelial cell damage, followed by increased leukocyte attachment and accumulation of macrophages and smooth muscle cells in lesions. Interestingly, II-13-induced atherosclerosis was blocked by pretreatment of animals with F(ab)2 segments derived from the antibody, but not mouse IgG F(ab)2.
  
  
  CONCLUSIONS
  Autoantibodies recognizing amino acid residues 288 to 366 of HSP60 induce atherosclerosis via the mechanisms of autoimmune reactions to HSP60 expressed on arterial endothelial cells, which can be prevented by F(ab)2 segments derived from these antibodies.
authors.affiliation: Department of Cardiac and Vascular Sciences, St. George's University of London, Cranmer Terrance, London SW17 0RE, UK.
authors.forename: Georgios
authors.initials: G
authors.lastname: Foteinos
authors.forename: Ali R
authors.initials: AR
authors.lastname: Afzal
authors.forename: Kaushik
authors.initials: K
authors.lastname: Mandal
authors.forename: Marjan
authors.initials: M
authors.lastname: Jahangiri
authors.forename: Qingbo
authors.initials: Q
authors.lastname: Xu
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D000918:Antibody Specificity; D001057:Apolipoproteins E / Q000235:genetics; D050197:Atherosclerosis / Q000276:immunology* / Q000473:pathology; D001323:Autoantibodies / Q000097:blood / Q000276:immunology / Q000494:pharmacology*; D002478:Cells, Cultured; D018834:Chaperonin 60 / Q000276:immunology*; D003327:Coronary Disease / Q000276:immunology* / Q000473:pathology; D004730:Endothelium, Vascular / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology / Q000494:pharmacology; D007074:Immunoglobulin G / Q000276:immunology / Q000494:pharmacology; D018793:Interleukin-13 / Q000494:pharmacology; D007763:Lac Operon; D051379:Mice; D008817:Mice, Mutant Strains; D008822:Mice, Transgenic; D012850:Sinus of Valsalva / Q000276:immunology / Q000473:pathology; D014471:Umbilical Veins / Q000166:cytology
chemical_list: D000911:Antibodies, Monoclonal; D001057:Apolipoproteins E; D001323:Autoantibodies; D018834:Chaperonin 60; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D018793:Interleukin-13